西洛他唑对脑梗死患者血小板聚集功能的影响及二级预防的作用

目的观察西洛他唑对脑梗死患者血小板聚集功能及二级预防的作用。方法选择在泰兴市人民医院神经内科住院的脑梗死患者72例，随机分为两组，治疗组在常规治疗的基础上予以西洛他唑100mg，早晚各1次；对照组予以拜阿司匹林100mg，每晚1片，分别在入院当时及服用药物后2、4、8、12、24周，监测血小板聚集功能、再次发生脑梗死及不良反应发生的情况。结果两组患者血小板聚集功能及再次发生脑梗死情况比较差异无统计学意义，但对照组有3例出现消化道出血，5例出现牙龈出血，而治疗组无一例出血情况的发生。结论西洛他唑更适宜应用于脑梗死患者的二级预防。

Effects of cilostazol on platelet aggregation and secondary prevention in patients with cerebral infarction

Objective To observe the effects of cilostazol on platelet aggregation and secondary prevention in patients with cerebral infarction. Methods Seventy-two patients with cerebral infarction hospitalized in people＇ s hospital of Taixing were ran- domly divided into two groups. Patients in the treatment group were treated with cilostazol 100 mg bid added to the conventional therapy, and patients in the control group were treated with bayaspirin enteric-coated tablets 100 mg qn. Platelet aggregation, the recurrent cerebral infarction and the adverse effects were monitored at the time of admission to hospital, and in 2 weeks, 4 weeks, 8weeks, 12 weeks and 24 weeks after taking medicine. Results There was no significant difference in the platelet aggre- gation and the rates of recurrent cerebral infarction between the two groups. But there were 3 cases of alimentary tract hemorrhage and 5 cases of gingival bleeding in the control group, while, none of bleeding happened in the treatment group. Conclusion Cilostazol is suitable for the secondary prevention of the patients with cerebral infarction.